Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients
| Status: | Terminated |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 45 |
| Updated: | 4/17/2018 |
| Start Date: | January 2002 |
| End Date: | March 1, 2018 |
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study
Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may
reduce their chance for getting pregnant. Their fertility can be preserved by stimulating
their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian
stimulation increase their estrogen levels in blood.this may stimulate their cancer and
increase chance for recurrence. If a medicine that prevent estrogen rise is used (letrozole),
this may increase the safety of stimulation. In this study we compared ovarian stimulation in
breast cancer patients using letrozole with those who did not undergo stimulation and showed
that there is no increase risk for recurrence after a median follow up of 2 years
reduce their chance for getting pregnant. Their fertility can be preserved by stimulating
their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian
stimulation increase their estrogen levels in blood.this may stimulate their cancer and
increase chance for recurrence. If a medicine that prevent estrogen rise is used (letrozole),
this may increase the safety of stimulation. In this study we compared ovarian stimulation in
breast cancer patients using letrozole with those who did not undergo stimulation and showed
that there is no increase risk for recurrence after a median follow up of 2 years
215 women with breast cancer were evaluated for fertility preservation before chemotherapy.
Of those, 79 elected to undergo controlled ovarian stimulation (COH) with letrozole and
gonadotropins for embryo or oocyte cryopreservation. The 136 patients who declined served as
controls.There were no significant differences between the study and control groups regarding
age at diagnosis, breast cancer prognostic parameters (tumor size, grade, number of positive
lymph nodes, estrogen receptor status, her2-neu overexpression and vascular space invasion),
and chemotherapy regimens. There was no difference between the two groups in the projected 10
year relapse, breast cancer specific mortality or overall mortality. There were 3 recurrences
or contralateral breast cancers (2 distant, 1 locoregional) in the letrozole group, and 11 in
the control group (9 distant, 1 locoregional, 1 contralateral breast).
Comparison; breast cancer patients that underwent ovarian stimulation with
letrozole+gonadotropins and those who declined ovarian stimulation.
Of those, 79 elected to undergo controlled ovarian stimulation (COH) with letrozole and
gonadotropins for embryo or oocyte cryopreservation. The 136 patients who declined served as
controls.There were no significant differences between the study and control groups regarding
age at diagnosis, breast cancer prognostic parameters (tumor size, grade, number of positive
lymph nodes, estrogen receptor status, her2-neu overexpression and vascular space invasion),
and chemotherapy regimens. There was no difference between the two groups in the projected 10
year relapse, breast cancer specific mortality or overall mortality. There were 3 recurrences
or contralateral breast cancers (2 distant, 1 locoregional) in the letrozole group, and 11 in
the control group (9 distant, 1 locoregional, 1 contralateral breast).
Comparison; breast cancer patients that underwent ovarian stimulation with
letrozole+gonadotropins and those who declined ovarian stimulation.
Inclusion Criteria:
- Age 18-45 years
- Biopsy proven breast cancer
- No prior chemotherapy or oophorectomy
- Regular menstrual cycles
- Normal basal FSH and estradiol
Exclusion Criteria:
- Stage 4 breast cancer
We found this trial at
1
site
